Pilar Font Ugalde-rekin lankidetzan egindako argitalpenak (3)

2023

  1. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain

    International Journal of Dermatology, Vol. 62, Núm. 5, pp. 700-706

2022

  1. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

    Life, Vol. 12, Núm. 11

  2. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

    Journal of Clinical Medicine, Vol. 11, Núm. 17